Contact Us
Drug Search Results
More Filters [+]

Radiprodil

Alternative Names: radiprodil, rgh-896, rgh896, rgh 896
Latest Update: 2024-12-14
Latest Update Note: Clinical Trial Update

Product Description

UCB is developing Radiprodil as a treatment for drug-resistant infantile spasms. (Sourced from: https://www.ucb.com/clinical-studies/Clinical-studies-index/Radiprodil)

Mechanisms of Action: NR2B Modulator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: UCB
Company Location: SMYRNA GA 30080
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Radiprodil

Countries in Clinic: Australia, Belgium, Canada, Germany, Italy, Netherlands, Poland, Spain, United Kingdom, United States

Active Clinical Trial Count: 9

Highest Development Phases

Phase 2: Malformations of Cortical Development|Seizures|Tuberous Sclerosis

Phase 1: Brain Cancer|Epilepsy, Absence|Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
Honeycomb

P1

Active, not recruiting

Seizures

2026-11-01

RAD-GRIN-201

P2

Unknown Status

Tuberous Sclerosis

2026-07-17

RAD-GRIN-101

P1

Unknown Status

Seizures

2025-11-30

RAD-GRIN-201

P2

Recruiting

Malformations of Cortical Development|Tuberous Sclerosis|Seizures

2025-07-01

Recent News Events

Date

Type

Title

12/09/2024

News Article

 GRIN Therapeutics Presents Data from Honeycomb Trial of Radiprodil at the American Epilepsy Society Annual Meeting

10/08/2024

News Article

 GRIN Therapeutics Announces Initiation of Astroscape Clinical Trial of Radiprodil for Treatment of Tuberous Sclerosis Complex and Focal Cortical Dysplasia Type II

09/09/2024

News Article

 GRIN Therapeutics Announces Positive Topline Data from Honeycomb Trial of Radiprodil in GRIN-Related Neurodevelopmental Disorder

08/20/2024

News Article

 GRIN Therapeutics to Present New Data from Honeycomb Study at ILAE Europe Epilepsy Congress

06/01/2024

PubMed

 Radiprodil, a selective GluN2B negative allosteric modulator, rescues audiogenic seizures in mice carrying the GluN2A(N615S) mutation.

08/30/2023

PubMed

 Pharmacological diversity amongst approved and emerging antiseizure medications for the treatment of developmental and epileptic encephalopathies.

03/01/2021

PubMed

 Use of a physiologically based pharmacokinetic-pharmacodynamic model for initial dose prediction and escalation during a paediatric clinical trial.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions